Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 2
2006 2
2012 1
2013 2
2014 2
2015 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.
Chalandon Y, Sbianchi G, Gras L, Koster L, Apperley J, Byrne J, Salmenniemi U, Sengeloev H, Aljurf M, Helbig G, Kinsella F, Choi G, Reményi P, Snowden JA, Robin M, Lenhoff S, Mielke S, Passweg J, Broers AEC, Kröger N, Yegin ZA, Tan SM, Hayden PJ, McLornan DP, Yakoub-Agha I; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Chalandon Y, et al. Am J Hematol. 2023 Jan;98(1):112-121. doi: 10.1002/ajh.26764. Epub 2022 Oct 31. Am J Hematol. 2023. PMID: 36266607 Free PMC article.
Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for chronic phase (CP) chronic myeloid leukemia (CML) has dramatically decreased. ...
Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantat …
Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT.
Chalandon Y, Passweg JR, Guglielmi C, Iacobelli S, Apperley J, Schaap NP, Finke J, Robin M, Fedele R, Bron D, Yakoub-Agha I, van Biezen A, de Witte T, Kröger N, Olavarria E; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Chalandon Y, et al. Haematologica. 2014 Sep;99(9):1492-8. doi: 10.3324/haematol.2013.100198. Epub 2014 Jul 4. Haematologica. 2014. PMID: 24997146 Free PMC article.
Patients with chronic myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation may be treated by tyrosine kinase inhibitors and/or by donor lymphocyte infusions. ...There appears to be no advantage from administering it early upon detection of mo …
Patients with chronic myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation may be treated by tyrosine …
Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation.
Auner HW, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N, Volin L, Janssen J, Nguyen Quoc S, Michallet M, Schoemans H, El Cheikh J, Petersen E, Guilhot F, Schönland S, Ahlberg L, Morris C, Garderet L, de Witte T, Kröger N; Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Auner HW, et al. Bone Marrow Transplant. 2013 Nov;48(11):1395-400. doi: 10.1038/bmt.2013.73. Epub 2013 May 27. Bone Marrow Transplant. 2013. PMID: 23708704
Hematopoietic stem cell transplantation for hematological malignancies in Europe.
Gratwohl A, Baldomero H, Passweg J, Frassoni F, Niederwieser D, Schmitz N, Urbano-Ispizua A; Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT); Working Parties Acute (ALWP) Chronic Leukemias (CLWP); Lymphoma Working Party. Gratwohl A, et al. Leukemia. 2003 May;17(5):941-59. doi: 10.1038/sj.leu.2402896. Leukemia. 2003. PMID: 12750709
Hematopoietic stem cell transplants (HSCTs) are considered the best treatment option for many hematological malignancies, and transplant numbers have increased five-fold during the last decade. ...These data give an overview of the current status of HSCT for hematological …
Hematopoietic stem cell transplants (HSCTs) are considered the best treatment option for many hematological malignancies, and transpl …
Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Kröger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T; Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Kröger N, et al. Bone Marrow Transplant. 2006 Jan;37(2):183-9. doi: 10.1038/sj.bmt.1705226. Bone Marrow Transplant. 2006. PMID: 16299545
Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants.
Gratwohl A, Hermans J, Niederwieser D, van Biezen A, van Houwelingen HC, Apperley J; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation EBMT. Gratwohl A, et al. Hematol J. 2001;2(6):363-70. doi: 10.1038/sj.thj.6200117. Hematol J. 2001. PMID: 11920275
We have analysed 782 patients, 438 males and 344 females, who were transplanted from HLA-identical female donors for CML in 1st chronic phase between 1989 and 1997. The risk of transplant related mortality (TRM) and relapse incidence (RI) were compared for male and female …
We have analysed 782 patients, 438 males and 344 females, who were transplanted from HLA-identical female donors for CML in 1st chronic …
A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia.
Piemontese S, Ciceri F, Labopin M, Bacigalupo A, Huang H, Santarone S, Gorin NC, Koc Y, Wu D, Beelen D, Tischer J, Ehninger G, Arcese W, Nagler A, Mohty M; Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). Piemontese S, et al. Leukemia. 2015 May;29(5):1069-75. doi: 10.1038/leu.2014.336. Epub 2014 Dec 1. Leukemia. 2015. PMID: 25434302
The 100-day CI of acute graft-versus-host disease (GvHD) was 323% for grade II-IV, 123% for grade III-IV. The 3-year CI of chronic GvHD was 343%. The 3-year CI of non-relapse mortality was 314% with in vivo T-cell depletion and 175% without. ...
The 100-day CI of acute graft-versus-host disease (GvHD) was 323% for grade II-IV, 123% for grade III-IV. The 3-year CI of chronic Gv …
Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings.
Kröger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A, Milpied N, Volin L, Mohty M, Leblond V, Blaise D, Finke J, Schaap N, Robin M, de Witte T; MDS subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Kröger N, et al. Leukemia. 2013 Mar;27(3):604-9. doi: 10.1038/leu.2012.210. Epub 2012 Jul 23. Leukemia. 2013. PMID: 22821073
Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors.
Hows JM, Passweg JR, Tichelli A, Locasciulli A, Szydlo R, Bacigalupo A, Jacobson N, Ljungman P, Cornish J, Nunn A, Bradley B, Socié G; IMUST Study Participating Centers; Late Effects Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Hows JM, et al. Bone Marrow Transplant. 2006 Dec;38(12):799-805. doi: 10.1038/sj.bmt.1705531. Epub 2006 Oct 30. Bone Marrow Transplant. 2006. PMID: 17075568
Thirty-nine centers provided data on 108 URD and 355 MSD recipients surviving more than 2 years. Long-term survival, performance status, chronic GvHD (c-GvHD), secondary malignancy, endocrine dysfunction, cataracts, bone necrosis and dental pathology were compared b …
Thirty-nine centers provided data on 108 URD and 355 MSD recipients surviving more than 2 years. Long-term survival, performance status, …
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.
Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, Valagussa P, Boccadoro M, Samson D, Bacigalupo A, Russell N, Montefusco V, Voena C, Gahrton G; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Corradini P, et al. Blood. 2003 Sep 1;102(5):1927-9. doi: 10.1182/blood-2003-01-0189. Epub 2003 May 8. Blood. 2003. PMID: 12738666 Free article. Clinical Trial.